Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.43 |
| ▸ | RAF1 | P04049 | 7/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | ABL1 | P00519 | 3/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.40 |
| ▸ | FPR2 | P25090 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | GABRE | P78334 | 1/20 | 0.39 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12329785 | 0.89 | NR4A1 (0.45) | MAPK14RAF1EPHX2ABL1GABRA1 | |
| SCHEMBL4328868 | 0.86 | P2RX3 (0.43) | MAPK14RAF1EPHX2ABL1BRAF | |
| SCHEMBL29834761 | 0.86 | P2RX3 (0.43) | MAPK14RAF1EPHX2ABL1BRAF | |
| SCHEMBL4202008 | 0.85 | RAF1 (0.44) | MAPK14RAF1EPHX2ABL1GABRA1 | |
| SCHEMBL9979938 | 0.83 | RAF1 (0.38) | MAPK14RAF1EPHX2ABL1GABRA1 | |
| SCHEMBL29834741 | 0.83 | PRKCZ (0.42) | MAPK14RAF1EPHX2GABRA1GABRG2 | |
| SCHEMBL28407664 | 0.82 | GRM5 (0.40) | MAPK14RAF1EPHX2ABL1SCN9A | |
| Methylamine SCHEMBL28986184 | 0.82 | PYGL (0.41) | MAPK14RAF1EPHX2ABL1BRAF | |
| SCHEMBL29834753 | 0.82 | ABL1 (0.46) | MAPK14RAF1EPHX2ABL1BRAF | |
| SCHEMBL400969 | 0.82 | RAF1 (0.47) | MAPK14RAF1EPHX2ABL1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078232-B2 | Preparation and use of molecular site targeted and activated kinase inhibitor | Yafei Shanghai Biology Medicine Science & Technology Co. Ltd. (CN) | 2021-08-03 | — | — | US | disclosed |
| US-20200140485-A1 | PREPARATION AND USE OF MOLECULAR SITE TARGETED AND ACTIVATED KINASE INHIBITOR | Yafei Shanghai Biology Medicine Science & Technology Co. Ltd. (CN) | 2020-05-07 | — | — | US | disclosed |
| US-20150175545-A1 | Preparation Method of Fluoro-Substituted Deuterated Diphenylurea | SUZHOU ZELGEN BIOPHARMACEUTICAL CO LTD (CN) | 2015-06-25 | — | — | US | disclosed |
| EP-2073811-B1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS LLC (US) | 2015-03-11 | — | — | EP | disclosed |
| US-8759531-B2 | Preparation method of fluoro-substituted deuterated diphenylurea | Suzhou Zelgen Biopharmaccceutical Co., Ltd. (CN) | 2014-06-24 | — | — | US | disclosed |
| US-8586565-B2 | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| WO-2013036232-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-03-14 | — | — | WO | disclosed |
| US-20130060043-A1 | PREPARATION METHOD OF FLUORO-SUBSTITUTED DEUTERATED DIPHENYLUREA | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD (CN) | 2013-03-07 | — | — | US | disclosed |
| CN-102803220-A | Synthetic method of fluorine-containing deuterated diphenylurea | SUZHOU ZELGEN BIOPHARMACEUTICAL CO LTD | 2012-11-28 | — | — | CN | disclosed |
| US-20120225057-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-09-06 | — | — | US | disclosed |
| US-20110136760-A1 | Kinase Inhibitors Useful for the Treatment of Myleoproliferative Diseases and other Proliferative Diseases | DECIPHERA PHARMACEUTICALS, LLC | 2011-06-09 | — | — | US | disclosed |
| US-7790756-B2 | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2073811-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008046003-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-04-17 | — | — | WO | disclosed |
| US-20080090856-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225057-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | ABL1, MCL1, ABL2 | MAPK14 323/4885RAF1 23/4885EPHX2 2736/4885 |
| US-20080090856-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES | MYLK3, MYLK, CDK3 | MAPK14 354/4885RAF1 176/4885EPHX2 3383/4885 |
| US-20130060043-A1 | PREPARATION METHOD OF FLUORO-SUBSTITUTED DEUTERATED DIPHENYLUREA | CCND3, UBE2D3, VDR | MAPK14 3540/4885RAF1 3715/4885EPHX2 1884/4885 |
| US-20110136760-A1 | Kinase Inhibitors Useful for the Treatment of Myleoproliferative Diseases and other Proliferative Diseases | MYLK3, MYLK, CDK3 | MAPK14 354/4885RAF1 176/4885EPHX2 3383/4885 |
| US-11078232-B2 | Preparation and use of molecular site targeted and activated kinase inhibitor | ACP1, PACSIN2, PKN2 | MAPK14 23/4885RAF1 127/4885EPHX2 3917/4885 |
| US-20200140485-A1 | PREPARATION AND USE OF MOLECULAR SITE TARGETED AND ACTIVATED KINASE INHIBITOR | ACP1, PACSIN2, PKN2 | MAPK14 23/4885RAF1 122/4885EPHX2 3843/4885 |
| US-20150175545-A1 | Preparation Method of Fluoro-Substituted Deuterated Diphenylurea | CCND3, UBE2D3, VDR | MAPK14 3540/4885RAF1 3715/4885EPHX2 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.